anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain Saiko-keishito (a Chinese herbal drug) effective for the mitigation of various symptoms of cold in the form of a liquid drug for internal use having good taste and flavor by compounding a specific sweetener of natural origin to an extract of Saiko-Keishito known as an excellent herbal drug. SOLUTION: An extract of Saiko-keishito is compounded with stevia. Saiko-keishito is a Chinese herbal drug preparation composed of Saiko (root of Bupleurum falcatum), Hange (rhizome of Pinellia ternata), Keishi (twig of Cinnamomum cassia), Shakuyaku (root of Paeonia albiflora), Ougon (root of Scutellaria baicalensis), Ninjin (root of Panax ginseng), Taisou (fruit of Zizyphus vulgaris), Kanzou (root of Glycyrrhiza glabra) and Kanshoukyou (rhizome of Zingiber officinale). Stevia is a sweetener composed mainly of a sweetener component existing in the leaf of Stevia Rebaudiana Bertoni which is a perennial plant of the family Compositae. The main components of the sweetener are stevioside, rebaudioside A, dulcoside A, rebaudioside E, steviol, etc., and especially a sweetener composed of 100% rebaudioside A is most preferable.  The amount of the stevia is preferably 5-100mg, especially 10-50mg per 30mL of the liquid drug for internal use from the viewpoint of the taste and flavor of the drug. The weight ratio of the raw crude drug of the Saiko-keishito to stevia is preferabley (100-3,500):1.
Strategies for controlling hypertension include reducing excess fat and increasing muscle mass. However, the effects of exercise interventions on hypertension in adolescents have been little investigated. The purpose was to evaluate the effect of 12 weeks of aerobic exercise on systolic blood pressure (SBP) and diastolic blood pressure (DBP) and the cardiometabolic profile of overweight hypertensive and non-hypertensive boys. The sample included 107 boys diagnosed as overweight, aged between 12 and 17, divided into two non-hypertension groups, one control (GCN, n = 14) and one with exercise (GEN, n = 55), as well as two groups of hypertensives, one control (GCH, n = 12) and one with exercise (GEH, n = 26). The boys were assessed at the study baseline and after 12 weeks in terms of anthropometric parameters, biological maturation, SBP, DBP and mean blood pressure (MBP), lipid, and metabolic profile. The aerobic training programs lasted 12 weeks and were carried out in three weekly sessions at different intensities. The high-intensity interval training session lasted around 35 min at an intensity of 80-100% of the reserve heart rate, and the moderate-intensity of continuous training session lasted 60 min at an intensity of 35-75% of the reserve heart rate. Caloric expenditure was equivalent between the exercises (p = 0.388). CGN and CGH participated only in school physical activities. Repeated measures analysis of variance and clinical effect analysis using Cohen's effect size were used, with a significance level established at p < 0.05. After 12 weeks, all groups increased their height (p < 0.05), but only the exercise groups showed a reduction in anthropometric variables (p < 0.05), with a possibly beneficial effect in GEN (d =  - 0.203; p = 0.003). No differences were found in the variables for the GCN. The GCH and GEH groups reduced SBP (p < 0.05), but only GEH showed a reduction in DBP (p = 0.005) and MBP (p = 0.001). In relation to the lipid profile, GEH maintained HDL-c close to baseline values, while GCH showed a reduction in HDL-c (p = 0.021). Regarding the clinical effect of exercise on hypertension, GEH showed a large and very beneficial effect size on DBP (d =  - 0.916; p = 0.006) and MBP (d =  - 0.926; p = 0.005).Conclusion: Hypertensive boys who practiced physical exercise showed greater effects in reducing blood pressure, indicating the importance of non-drug therapeutic management in overweight adolescents.Trial registration:Brazilian Registry of Clinical Trials RBR-4v6h7b / RBR-6343y7.
This is a 2-year, multicenter, prospective (look forward using periodic observations collected predominantly following patient enrollment), longitudinal (it is a co relational research study that involves repeated observations of the same variables over long periods of time), and observational study. The objective of this study is to examine the patients with mild and moderate AD who are currently being treated with different treatment care methods in real-world settings. Doctors will not be provided medication or asked to treat their patients with any particular treatment. The effect of the different management strategies on cognition, activities of daily living, and behavior of the patients will be evaluated, and data on the informal caregiver burden will be assessed. Data on the utilization of health and social care services by the patient and the primary informal caregiver, including admission of the patient to an assisted living facility or nursing home will be assessed. The doctor's assessment of clinical global impression and adverse events will also be documented. Data will be collected from the doctors at baseline and at 6, 12, and 24 months, and from the caregivers at baseline and 6, 12, 18, and 24 months. The medication dosage and administration is based upon the doctors' prescription, individualized for the patient and not dictated by the protocol.
Kidney toxicity was observed in animals who received golodirsen [see Use in Specific Populations (8.4)]. Although kidney toxicity was not observed in the clinical studies with VYONDYS 53, the clinical experience with VYONDYS 53 is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking VYONDYS 53. Because of the effect of reduced skeletal muscle mass on creatinine measurements, creatinine may not be a reliable measure of kidney function in DMD patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VYONDYS 53. Consider also measuring glomerular filtration rate using an exogenous filtration marker before starting VYONDYS 53. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio every three months. Only urine expected to be free of excreted VYONDYS 53 should be used for monitoring of urine protein. Urine obtained on the day of VYONDYS 53 infusion prior to the infusion, or urine obtained at least 48 hours after the most recent infusion, may be used. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, as this reagent has the potential to cross react with any VYONDYS 53 that is excreted in the urine and thus lead to a false positive result for urine protein. 

If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.
Follow-up results from the PHOENIX study failed to show statistical superiority of intraperitoneal paclitaxel plus systemic chemotherapy. However, in the subgroup analysis, it can be seen that after correcting for the bias effect of ascites, the difference between the two groups was statistically significant, further proving the significance of ascites control on the prognosis of patients with gastric cancer peritoneal metastasis. Based on the existing data, for patients with moderate amount of ascites, the IP regimen is recommended to control ascites and relieve ascites. Symptoms, purpose of improving quality of life and prolonging survival. HIPEC is traditionally used to treat peritoneal cancer. Patients who diagnosed with gastric cancer with peritoneal metastasis were divided into two groups based on whether they underwent HIPEC. The primary endpoint is the R0 resection rate and the secondary endpoints are 1-year overall survival, and Safety.
A method is described herein that comprises receiving scanned documents, wherein the scanned documents comprise unstructured data. The method includes performing optical character recognition of the scanned documents to produce text data for each page of the scanned documents, wherein the text data for each page comprises a sequence of words stored together with their location. The method includes dividing each page of the scanned documents into subsections. The method includes using the text data to identify a structure type of each subsection of a page, wherein the structure type includes at least one of a table and text paragraph. The method includes using the text data to label each subsection of a page with a semantic type, wherein the semantic type defines a context surrounding collection of information in a subsection. The method includes using the text data for each subsection of a page to identify medical concepts.
The invention relates to a preparation method and use of 4'-methoxyl chalcone compounds. The 4'-methoxyl chalcone compounds are prepared by the step of carrying out a condensation reaction on seven different para-substituted benzaldehyde as raw materials and 4-methoxyl acetophenone to generate a target product in the existence of alkali. The compounds can activate the activity of tyrosinase, and meanwhile increase melanin content in cells and can be used for clinically preparing medicines for treating leucoderma. In vitro tyrosinase activity test is carried out for the synthesized compounds, and tests on tyrosinase and melanin content in B16 melanoma cells are further carried out. The experimental results show that the compounds 2f and 2g have a certain effect of activating the activity of tyrosinase. The compound 2d has a better effect of activating the activity of tyrosinase. The compounds 2b, 2e, 2f and 2g have certain proliferation effects to tyrosinase and melanin content in B16 melanoma cells of mice in a low concentration range of 5-20mu g/ml.
Colistimethate for Injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa. This antibiotic is not indicated for infections due to Proteus or Neisseria. Colistimethate for Injection, USP has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.

Colistimethate for Injection, USP may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. 

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Colistimethate for Injection, USP and other antibacterial drugs, Colistimethate for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving CS or to a control group receiving treatment as usual. Participants in the intervention group will participate in two CS sessions per week for 16 weeks besides their treatment as usual. The sessions will be based on the existing protocol.
The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.100U Botulinum toxin type A(BTA) will be reconstituted with 2mL of normal saline for a concentration of 50U/mL. 0.1ml(5 units) of BTA will be injected along the wound edges. The injections will be administered within 14 days of median sternotomy with a 30G needle.
The investigators apply the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria to recruit the biomarker-defined, young-onset AD patients with intermediate-to-high levels of biological evidence. This is a randomized, sham-controlled, 2-way crossover study, and combined neuroimaging study of 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) to further explore the potential mechanisms. This study will consist of two intervention periods. A total of 50 young-onset AD patients will be consecutively recruited and be randomized into one of two groups: active and sham stimulation (n = 25 per group) in every intervention period. Besides, 20 cognitively normal subjects will be recruited for neuroimaging comparison. Cognitive evaluation will be performed before and immediately after treatment at 2 weeks of TBS intervention, and 4 weeks after TBS. Data on functional neuroimaging will be also collected before and after TBS protocol.
Phase I/II label single arm safety assessment study of Siplizumab-based conditioning. It is designed to determine the safety and feasibility of hematopoietic stem cell transplantation for patients with advanced sickle cell disease using in vivo T cell depletion with Siplizumab.

It is a three-stage design with a target sample size of at most 18 patients. At the first stage, a total of 6 patients will be recruited, the study will be stopped, if 2 or more of patients experience any of the following events: graft failure/Grade 3-4 acute GVHD/death in the first 100 days. If not, the study will proceed to the second stage and recruit additional 6 patients. The study will be stopped if 4 or more patients experience an event as specified above among the 12 patients. If not, the study will proceed to the third stage and recruit additional 6 patients, the study will be stopped any time if 6 or more patients experience an event among the 18 patients. The study will be stopped at any time if a patient death occurs.
Esters of the antibiotic pleuromutilin or its hydrogenation product are obtained by reacting pleuromutilin or its hydrogenation product with an ester-forming derivative of an acid selected from isocyanic acid, an aliphatic monocarboxylic acid having from 3 to 19 carbon atoms, a haloformic acid or monohaloacetic acid, an aliphatic dicarboxylic acid having from 3 to 14 carbon atoms, or a sulphonic acid.  The acid may contain an additional group capable of reacting with a base to form a salt; in which case, the first-formed ester is reacted with a base to form the salt.  The ester of the hydrogenation product of pleuromutilin may be produced by forming the ester of pleuromutilin and hydrogenating the ester before or after treatment with the base to form the salt.  Pleuromutilin has the formula <FORM:1111009/C2/1> On hydrogenation the vinyl group of pleuromutilin is hydrogenated to an ethyl group. Pleuromutilin, originally named antibiotic BC 757, was produced by the cultivation of Clitopilus passeckerianus (Pil.) Sing. NRRL 3100 in accordance with Specification 1,111,010. Typical esters are the succinate, monopalmitate, a  - carboxyethylcarbamate, 1,3 - dicarboxypropylcarbamate, beta - sulphopropionate and m-sulphobenzoate.  An animal feed or feed supplement comprises one or more esters of pleuromutilin or its hydrogenation product. Conventional feed supplements containing penicillium mycelia may be used.
Single-therapy group: single anticoagulant drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those \<70 years and 1.6-2.6 for those =\>70 years is recommended according to the Japanese guidelines.
PURPOSE: To obtain an application agent for medical use, having a sufficient tackiness without causing the peeling, etc., in application thereof, to which a wide range of pharmacodynamically effective ingredients can be applied and further having low irritancy by blending an N-vinylacetamide-acrylic acid (salt) copolymer with titanium oxide. CONSTITUTION: This application agent for medical use is obtained by blending 100 pts.wt. N-vinylacetamide-acrylic acid (salt) copolymer with 5-120 pts.wt. titanium oxide and forming the resultant plaster on a support. The weight ratio of the N-vinylacetamide to the acrylic acid (salt) in the copolymer is preferably (99.9:0.1) to (80:20). Metallic cross-linking is carried out as a method for cross-linking the N-vinylacetamide-acrylic acid (salt) copolymer using a polyvalent metallic compound such as aluminum oxide. A film such as a polyester or a polyurethane, a cotton cloth, a nonwoven fabric and a laminate are cited as the support for the application agent. The tackiness of the application agent is remarkably improved by blending the copolymer with titanium oxide.
OBJECTIVE: Acute myocardial infarction (AMI) is a severe cardiovascular disease that threatens human life and health globally. N6-methyladenosine (m6A) governs the fate of RNAs via m6A regulators. Nevertheless, how m6A regulators affect AMI remains to be deciphered. To solve this issue, an integrative analysis of m6A regulators in AMI was conducted.
METHODS: We acquired transcriptome profiles (GSE59867, GSE48060) of peripheral blood samples from AMI patients and healthy controls. Key m6A regulators were used for LASSO, and consensus clustering was conducted. Next, the m6A score was also computed. Immune cell infiltration, ferroptosis, and oxidative stress were evaluated. In-vitro and in-vivo experiments were conducted to verify the role of the m6A regulator ALKBH5 in AMI.
RESULTS: Most m6A regulators presented notable expression alterations in circulating cells of AMI patients versus those of controls. Based on key m6A regulators, we established a gene signature and a nomogram for AMI diagnosis and risk prediction. AMI patients were classified into three m6A clusters or gene clusters, respectively, and each cluster possessed the unique properties of m6A modification, immune cell infiltration, ferroptosis, and oxidative stress. Finally, the m6A score was utilized to quantify m6A modification patterns. Therapeutic targeting of ALKBH5 greatly alleviated apoptosis and intracellular ROS in H/R-induced H9C2 cells and NRCMs.
CONCLUSION: Altogether, our findings highlight the clinical significance of m6A regulators in the diagnosis and risk prediction of AMI and indicate the critical roles of m6A modification in the regulation of immune cell infiltration, ferroptosis, and oxidative stress.
NEW MATERIAL:A compound of formula I (R is H, methyl; the dotted lines mean that double bonds are between the 2-3 or 3-4 positions). EXAMPLE:1,3-Dimethyl-4-(1-oxo-3-butenyl)-1-cyclohexene. USE:Durative smell or flavor intensifier or modifier: it has flower-like or fruit- like smell, moreover the smell is durative. It can develop excellent effects over a wide range of fields such as hygiene and medicines. PREPARATION:The reaction of 1,3-dimethyl-4-formyl-1-cyclohexene of formula 3 with an allylmagnesium halide of formula 4 (X is halogen) is carried out in an organic solvent such as benzene at -20- about 60 deg.C for about half to 5hr to give a compound of formula 2. The product is oxidized in a solvent such as acetone with chromic anhydride to give the compound of formula 1-2. The compound of formula 1-2 is isomerized in the presence of a catalyst such as sulfuric acid to give the compound of formula 1-1.
FIELD: chemistry.SUBSTANCE: invention relates to a method of making a restoration from a workpiece consisting of lithium silicate glass ceramic or containing lithium silicate glass ceramics, and using a workpiece obtained using said method. Method involves melting the initial lithium silicate glass, cooling the glass mass quickly and grinding it into powder. At least two layers of powder made from initial lithium-silicate glass from different compositions are loaded into the mould in layers. After the first layer is loaded, its surface is smoothed and then structured so that said first layer, when viewed along the surface, differs in its height from one section to another so that protrusions separated by depressions are formed. Then, as a second layer, the layer is loaded with a layer having a composition different from the composition of the first layer, or after adding the first layer, an additional layer of powder is loaded into the mould, wherein the material of the additional layer is the same as the second layer, the material of the first layer is mixed with the material of the additional layer to form an intermediate layer and then a second layer is loaded into the mould. After introduction of layers, they are pressed to form mass and then subject to sintering with formation of workpiece. Dental restoration is made of the workpiece by means of mechanical treatment. Composition of initial glass contains, or consists of the following, in percentage by weight: SiO57.5–60.5; LiO 14.0–16.0; ZrO9.0–10.5; PO5.0–6.0; AlO2.5–3.0; KO 1.0–1.5; CeO0.5–1.0; BO2.5–3.0; NaO 0.1–2.0; VO0.1–0.7; ErO0–1.0; YO0.3–0.5; MnO0–0.2.EFFECT: development of the method using a workpiece in order to obtain dental restorations of the required dimensions without difficulties, at the same time by means of simple measures the required colouring and/or light transmission can be obtained, as well as absence of the need for additional stages of heat treatment.19 cl, 4 dwg
An object of the present invention is to provide a Trehangelin-containing skin cleansing agent and a lamellar formation promoting agent. As a solution, the present invention provides: 1. A Trehangelin-containing skin cleansing agent and a lamellar formation promoting agent. 2. The skin cleansing agent according to 1, wherein the content of Trehangelin with respect to the total amount of the skin cleansing agent is 0.001% by mass or more and 10% by mass or less. 3. The skin cleansing agent according to 1 or 2, which contains and anionic surfactant. 4. The skin cleansing agent according to any one of 1 to 3, wherein the content of Trehangelin A with respect to the total amount of Trehangelin is 40% or more and 80% or less.
Current research suggests that levels of brain-derived neurotrophic factor (BDNF) and certain excitatory neurotransmitters - specifically glutamate, D-serine, and glycine are low in participants with depression and other mental illnesses (Wolkowitz and Reus 2002, Tan et al., 2005; Shoval \& Weizman, 2005; Hashimoto et al., 2005). Research also suggests that levels of both BDNF and excitatory transmitters can be enhanced by cognitive stimulation (Hynd et al., 2005; Wu et al., 2005; Yang et al., 2005; Mattson et al., 2004). BDNF is found in brain tissue and is also measurable in blood; it stimulates neuronal cell growth in certain brain regions (Duman, 2004). In Phase 1, we wish to measure the levels of specific neurotrophic factors in healthy, young participants. Phase 2 is intended to correlate similar levels with change in neurocognitive performance in healthy, older participants. Overall, this study is designed to obtain a raw measure of the impact that cognitive training has on the mature adult brain.